Akebia Therapeutics Inc. (NASDAQ:AKBA) has a beta value of 0.78 and has seen 2.35 million shares traded in the last trading session. The company, currently valued at $306.02M, closed the last trade at $1.46 per share which meant it gained $0.08 on the day or 5.80% during that session. The AKBA stock price is -69.86% off its 52-week high price of $2.48 and 46.58% above the 52-week low of $0.78. If we look at the company’s 10-day average daily trading volume, we find that it stood at 2.97 million shares traded. The 3-month trading volume is 3.24 million shares.
The consensus among analysts is that Akebia Therapeutics Inc. (AKBA) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 4 have rated it as a Hold, with 4 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.05.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Akebia Therapeutics Inc. (NASDAQ:AKBA) trade information
Sporting 5.80% in the green in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the AKBA stock price touched $1.46. Year-to-date, Akebia Therapeutics Inc. shares have moved 17.74%, while the 5-day performance has seen it change 2.82%. Over the past 30 days, the shares of Akebia Therapeutics Inc. (NASDAQ:AKBA) have changed 60.44%. Short interest in the company has seen 13.11 million shares shorted with days to cover at 3.4.
Wall Street analysts have a consensus price target for the stock at $6.5, which means that the shares’ value could jump 77.54% from current levels. The projected low price target is $6 while the price target rests at a high of $7. In that case, then, we find that the current price level is -379.45% off the targeted high while a plunge would see the stock gain -310.96% from current levels.
Akebia Therapeutics Inc. (AKBA) estimates and forecasts
Figures show that Akebia Therapeutics Inc. shares have underperformed across the wider relevant industry. The company’s shares have gained 5.04% over the past 6 months, with this year growth rate of 0.00%, compared to 13.30% for the industry. Revenue growth from the last financial year stood is estimated to be -11.40%.
3 analysts offering their estimates for the company have set an average revenue estimate of 49.45M for the current quarter. 3 have an estimated revenue figure of 44.71M for the next ending quarter. Year-ago sales stood 56.38M and 42.05M respectively for this quarter and the next, and analysts expect sales will shrink by -12.30% for the current quarter and -11.40% for the next.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 35.46% over the past 5 years.
AKBA Dividends
Akebia Therapeutics Inc. is expected to release its next earnings report in August this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Akebia Therapeutics Inc. (NASDAQ:AKBA)’s Major holders
Insiders own 2.14% of the company shares, while shares held by institutions stand at 27.05% with a share float percentage of 27.64% . Investors are also buoyed by the number of investors in a company, with Akebia Therapeutics Inc. having a total of 129 institutions that hold shares in the company. The top two institutional holders are ALERCE INVESTMENT MANAGEMENT, L.P. with over 13.21 million shares worth more than $24.17 million. As of 2024-03-31, ALERCE INVESTMENT MANAGEMENT, L.P. held 6.9536% of shares outstanding.
The other major institutional holder is VANGUARD GROUP INC, with the holding of over 8.23 million shares as of 2024-03-31. The firm’s total holdings are worth over $15.05 million and represent 4.3317% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund . As of Mar 31, 2024 , the former fund manager holds about 2.55% shares in the company for having 5.34 shares of worth $7.79 million while later fund manager owns 2.6 shares of worth $3.8 million as of Mar 31, 2024 , which makes it owner of about 1.24% of company’s outstanding stock.
